Evidence on sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists indicates that these drugs can be used not just for glucose control but for cardiovascular (CV) risk reduction in patients with type
Randomized trial participants with type 1 diabetes and mild-to-moderate diabetic kidney disease who received allopurinol or placebo had similar estimated glomerular filtration rates after three years.
Incorporating intensive weight management with a low-carb diet into standard group medical visits for patients with diabetes “should be considered as an alternative, noninferior approach for glycemic management that has additional clinical
Patients with type 1 diabetes who were randomly assigned to insulin treatment with a closed-loop system spent more time in the target glycemic range than those assigned to a sensor-augmented pump.
A narrative review considered the available evidence on use of metformin, thiazolidinediones, sulfonylureas, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors in the hospital.
In a longitudinal study of 21,531 patients, those in poor or intermediate health at age 75 years were more likely to use insulin than those in good health (29.4% and 27.5% versus 10.5%, respectively) and less likely to discontinue it during follow-up
An accompanying editorial noted that the results from this Chinese study highlight the need for a global emphasis on preventing cardiovascular disease.
While we could not determine causality between insulin and mortality, we highlight a vulnerable population which needs additional resources in the discharge transition period,” the authors wrote.
The results highlight the underappreciated burden of diabetic foot hospitalizations not associated with amputation, the authors said.
In a survey of U.S. adults with diabetes, about 13% who were prescribed medication said they did not take it as prescribed, and about 24% said they asked their doctors for a lower-cost medication.